Heidelberg Pharma AG (HPHA) - Total Liabilities

Latest as of May 2025: €43.94 Million EUR ≈ $51.37 Million USD

Based on the latest financial reports, Heidelberg Pharma AG (HPHA) has total liabilities worth €43.94 Million EUR (≈ $51.37 Million USD) as of May 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Heidelberg Pharma AG working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Heidelberg Pharma AG - Total Liabilities Trend (2016–2024)

This chart illustrates how Heidelberg Pharma AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Heidelberg Pharma AG asset portfolio.

Heidelberg Pharma AG Competitors by Total Liabilities

The table below lists competitors of Heidelberg Pharma AG ranked by their total liabilities.

Company Country Total Liabilities
Leoch International Technology Limited
F:0LT
Germany €10.68 Billion
Companhia Estadual de Distribuição de Energia Elétrica
SA:CEED3
Brazil R$14.38 Billion
Inclusio Sca
BR:INCLU
Belgium €168.45 Million
ADC Therapeutics SA
NYSE:ADCT
USA $507.87 Million
General de Alquiler de Maquinaria SA
MC:GAM
Spain €454.34 Million
GR Silver Mining Ltd
V:GRSL
Canada CA$1.25 Million
Schwager
SN:SCHWAGER
Chile CL$43.61 Billion
LEWAG Holding Aktiengesellschaft
F:KGR
Germany €68.17 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Heidelberg Pharma AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Heidelberg Pharma AG to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 7.74 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.37 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.70 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Heidelberg Pharma AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Heidelberg Pharma AG (2016–2024)

The table below shows the annual total liabilities of Heidelberg Pharma AG from 2016 to 2024.

Year Total Liabilities Change
2024-11-30 €29.85 Million
≈ $34.90 Million
+42.08%
2023-11-30 €21.01 Million
≈ $24.57 Million
-38.08%
2022-11-30 €33.94 Million
≈ $39.68 Million
+125.75%
2021-11-30 €15.03 Million
≈ $17.58 Million
+123.39%
2020-11-30 €6.73 Million
≈ $7.87 Million
+0.49%
2019-11-30 €6.70 Million
≈ $7.83 Million
+26.22%
2018-11-30 €5.31 Million
≈ $6.20 Million
+18.81%
2017-11-30 €4.47 Million
≈ $5.22 Million
-18.58%
2016-11-30 €5.49 Million
≈ $6.41 Million
--

About Heidelberg Pharma AG

F:HPHA Germany Biotechnology
Market Cap
$133.46 Million
€114.15 Million EUR
Market Cap Rank
#18178 Global
#1690 in Germany
Share Price
€2.44
Change (1 day)
+1.67%
52-Week Range
€2.31 - €3.47
All Time High
€8.94
About

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amaniti… Read more